Opko Acquires Brazilian Pharma Company, Clearing Way for Launch of 4kscore Prostate Cancer Test | GenomeWeb

Opko Health said it has completed the acquisition of the Brazilian pharmaceutical firm Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos.

The acquisition will allow Opko to commercialize its Opko 4kscore prostate cancer diagnostic in Brazil as a laboratory-developed test while it obtains Brazilian approval for an in vitro diagnostic version of the product.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.